Vancouver, British Columbia--(Newsfile Corp. - February 6, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce that it has completed initial sales of VIVI Cap, VIVI Cap Smart, VIVI Epi, and VIVI Med to pharmacies operated by Maccabi Healthcare Services ("Maccabi") and has launched a national in-pharmacy marketing campaign to put its products ...

Roadshow presentation Q1 2025/26 Making life easier Impact4: Setting the standard of care at scale Tomoko | User, Voice & Respiratory Care Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements are based on Coloplast's current expectations, estimates and assumptions ...

Core Insights - Coloplast reported Q1 organic growth of 6% and EBIT growth in constant currencies of 3%, with a return on invested capital of 15% [1][9] Financial Performance - Reported revenue in DKK grew 0%, impacted by a 4 percentage points negative effect from currencies [1] - EBIT was DKK 1,850 million, with a reported EBIT margin of 26%, down from 27% last year [4] - Free cash flow-to-sales ratio improved to 26% from 24% last year [9] Business Area Performance - Ostomy Care experienced a soft start with 4% growth, affected by negative growth in China and a high baseline in the US [2] - Continence Care grew by 7%, driven by strong contributions from Luja™ [2] - Voice & Respiratory Care saw an 8% increase, supported by growth in Laryngectomy [2] - Wound & Tissue Repair had a mixed performance, with Kerecis showing 10% organic growth but facing challenges due to Medicare reimbursement changes [2][3] - Advanced Wound Dressings declined by 3% due to product returns in China, impacting revenue by approximately DKK 25 million [3] - Interventional Urology showed strong growth, particularly in the US Men's Health business [3] Future Guidance - FY 2025/26 guidance remains unchanged, targeting around 7% organic revenue growth and EBIT growth in constant currencies [6] - Kerecis is now expected to deliver around 10% growth, down from a previous estimate of 25% due to sales disruptions [7] - Reported growth in DKK is anticipated at around 4%, with a negative currency impact of approximately 3 percentage points [7] Strategic Developments - Coloplast US plans to acquire Uromedica, a company specializing in stress urinary incontinence treatment, expected to close in February 2026 [5]

Core Insights - Envista (NVST) reported revenue of $750.6 million for Q4 2025, marking a 15% year-over-year increase and exceeding the Zacks Consensus Estimate by 11.16% [1] - The company's EPS for the quarter was $0.38, up from $0.24 a year ago, representing an EPS surprise of 18.23% over the consensus estimate of $0.32 [1] Financial Performance - Revenue from Equipment & Consumables was $274.7 million, surpassing the average estimate of $248.55 million by analysts, reflecting a year-over-year increase of 13.5% [4] - Revenue from Specialty Products & Technologies reached $475.9 million, exceeding the average estimate of $429.04 million, with a year-over-year change of 15.8% [4] - Adjusted Operating Profit for Equipment & Consumables was reported at $55.2 million, compared to the average estimate of $52.56 million [4] - Adjusted Operating Profit for Specialty Products & Technologies was $77 million, exceeding the average estimate of $59.59 million [4] Market Performance - Envista's shares have returned +3.2% over the past month, outperforming the Zacks S&P 500 composite's +0.5% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Integer Holdings Corporation (NYSE: ITGR) between July 25, 2024 and October 22, 2025, both dates inclusive (the “Class Period”), of the important February 9, 2026 lead plaintiff deadline. SO WHAT: If you purchased Integer common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a ...

RANCHO SANTA MARGARITA, Calif.--(BUSINESS WIRE)--Applied Medical Prevails in Antitrust Jury Trial Against Medtronic. ...

Core Insights - Pulse Biosciences, Inc. has announced late-breaking clinical data from its nPulse Cardiac Catheter first-in-human feasibility study, showcasing the successful treatment of atrial fibrillation in 150 patients [1] - The study highlights rapid procedure times and minimal adverse effects associated with the use of the proprietary Nanosecond Pulsed Field Ablation technology [1] Company Overview - Pulse Biosciences, Inc. is focused on developing innovative medical technologies, specifically utilizing nanosecond PFA energy for cardiac treatments [1] - The company is publicly traded on Nasdaq under the ticker symbol PLSE [1] Clinical Study Details - The feasibility study involved 150 patients and demonstrated effective treatment outcomes for atrial fibrillation [1] - The results were presented at the 31st Annual event, indicating the significance of the findings in the medical community [1]

Core Viewpoint - Medical technology company Medtronic has been ordered to pay $382 million in damages to Applied Medical Resources for unlawfully monopolizing the market for blood-vessel sealing surgical devices [1] Group 1: Legal and Financial Implications - The ruling highlights significant legal challenges for Medtronic in maintaining its market position [1] - The $382 million damages could impact Medtronic's financial performance and investor confidence [1] Group 2: Market Dynamics - The case underscores competitive pressures in the medical device industry, particularly in the blood-vessel sealing segment [1] - The outcome may influence future market strategies and pricing for surgical devices among competitors [1]

Core Insights - Embecta is transitioning from a "stand-up" phase to a "seed growth" phase, focusing on stabilizing its core insulin delivery franchise and expanding its portfolio while enhancing financial flexibility [4][7]. Branding and Transition - More than 95% of U.S. and Canadian revenue has transitioned to the Embecta brand, with international rollouts expected to be substantially complete by the end of calendar year 2026 [1]. Financial Performance - For Q1 fiscal 2026, Embecta reported approximately $261 million in revenue, a 2% decline on an adjusted constant-currency basis, with U.S. revenue down 7.6% due to pricing and volume headwinds, while international sales grew [6][10]. - GAAP net income was $44.1 million, with adjusted EPS at $0.71, reflecting an improvement from the previous year [5][15]. - The company generated about $17 million in free cash flow and repaid approximately $38 million of debt, reducing net leverage to about 2.8x [5][16]. Product and Market Strategy - Embecta is pursuing a GLP-1 strategy to extend its insulin delivery capabilities, collaborating with over 30 pharmaceutical partners, with initial generic GLP-1 launches anticipated in markets like Canada, Brazil, China, and India starting in 2026 [17][18]. - The company is also focusing on expanding its product offerings, including market-appropriate pen needles and syringes, and has begun discussions on co-packaging opportunities with branded pharmaceutical companies [21]. Guidance and Expectations - For fiscal 2026, Embecta reaffirmed its guidance, expecting adjusted constant-currency revenue to be flat to down 2% year over year, with as-reported revenue projected between $1.071 billion and $1.093 billion [22]. - The company anticipates generating $180 million to $200 million in free cash flow and repaying about $150 million of debt in fiscal 2026 [23].

Toronto, Ontario--(Newsfile Corp. - February 5, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company") is initiating a temporary halt on its devices in Canada due to the lapse of its license with Health Canada. The Company's Health Canada Licence became expired due to an untimely certificate renewal. This is not a suspension or cancellation related to regulatory compliance or enforcement action. The temporary status does not constitute a product safety risk. However, to remain compliant ...